GHB, GBL and 1,4-BD addiction

Current Pharmaceutical Design

Volumn 20, Issue 25, 2014, Pages 4076-4085

  Brunt, Tibor M ^a   van Amsterdam, Jan G C ^b,d   van den Brink, Wim ^c,d  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

1,4 BD; Addiction; Dependence; Dopamine; Gaba; GBL; GHB; Illicit drugs; Withdrawal

Indexed keywords

1,4 BUTANEDIOL; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; AUTORECEPTOR; BACLOFEN; BENZODIAZEPINE DERIVATIVE; COCAINE; DIAZEPAM; DOPAMINE; G PROTEIN COUPLED RECEPTOR; GAMMA BUTYROLACTONE; HYPNOTIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXAZEPAM; OXYBATE SODIUM; PENTOBARBITAL; RECREATIONAL DRUG; 1,4-BUTANEDIOL; 4-HYDROXYBUTYRIC ACID; BUTANEDIOL; HYDROXYBUTYRIC ACID;

4 AMINOBUTYRIC ACID RELEASE; ACUTE TOXICITY; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; BASAL METABOLIC RATE; CLINICAL FEATURE; DISCRIMINATIVE STIMULUS; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DISCRIMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG USE; EMERGENCY; HIGH RISK BEHAVIOR; HUMAN; INSOMNIA; MULTIPLE DRUG ABUSE; NARCOLEPSY; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PHYSICIAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SENSATION SEEKING; SYSTEMATIC REVIEW (TOPIC); WITHDRAWAL SYNDROME; ANIMAL; METABOLISM; SUBSTANCE-RELATED DISORDERS;

4-BUTYROLACTONE; ANIMALS; BUTYLENE GLYCOLS; HUMANS; HYDROXYBUTYRATES; SUBSTANCE-RELATED DISORDERS;

EID: 84904055898     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990624     Document Type: Review

References (146)

1. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964; 3: 433-451.
2. Kam PC, Yoong FF. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998; 53: 1195-1198.
3. Gallimberti L, Spella MR, Soncini CA, et al. Gammahydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000; 20: 257-262.
4. Caputo F, Vignoli T, Maremmani I, et al. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health 2009; 6: 1917-1929.
5. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006; 29: 939-946.
6. Black J, Pardi D, Hornfeldt CS, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med 2010; 6: 596-602.
7. Sumnall HR, Woolfall K, Edwards S, et al. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92: 286-290.
8. van Amsterdam JGC, van Laar M, Brunt TM, et al. Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. Regul Toxicol Pharmacol 2012; 63: 55-63.
9. Hurlbut KM, Silverstein S. Gamma butyric acid and related compounds. Hurlbut KM, Silverstein S. Eds. poisindex. In: Toll LL & Hurlbut KM (Eds): POISINDEX® System. MICROMEDEX, Inc., Greenwood Village, Colorado (Edition expires 6/2000). 2000.
10. Irwin RD. NTP Summary Report on the Metabolism, Disposition, and Toxicity of 1,4-Butanediol. NIH Publication No. 96-3932. United States Departement of Helath and Human Services, Public Health Sevice, National Institute of Health. Available from: http://www.ntp.niehs.nih.gov/ntp/htdocs/ST_rpts/tox054.pdf. [Accessed 3 April 2013]. 1996.
11. Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344: 87-94.
12. Gónzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005; 19: 195-204.
13. Lora-Tamayo C, Tena T, Rodríguez A, et al. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133: 256-9.
14. Dart RC. Medical Toxicology. Medical Toxicology. Baltimore/London, Lippincott Williams & Wilkins, 3 ed. 2004; 1096-102.
15. EMCDDA. European Information Centre and Database on New Drugs. EMCDDA Early Warning System about GHB. 2011.
16. Abanades S, Farre M, Barral D, et al. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J Clin Psychopharmacol 2007; 27: 625-638.
17. Wong CGT, Chan KFY, Gibson KM, et al. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev 2004; 23: 3-20.
18. Elliott SP. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26: 432-440.
19. Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand 2010; 54: 987-992.
20. Lenz D, Rothschild M, Kroener L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gammahydroxybutyric acid and gamma-butyrolactone. Ther Drug Monit 2008; 30: 755-761.
21. Liechti ME, Kunz I, Greminger P, et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Dep 2006; 81: 323-326.
22. Zvosec DL, Smith S, Porrata T, et al. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29: 319-332.
23. Ricaurte GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet 2005; 365: 2137-2145.
24. Kim SY, Anderson IB, Dyer JE, et al. High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users. Am J Drug Alcohol Abuse 2007; 33: 429-438.
25. Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23: 316-320.
26. van Laar MW, Cruts AAN, van Ooyen-Houben MMJ, et al. Netherlands national drug monitor; NDM annual report 2011. Trimbos Institute, Utrecht, The Netherlands 2012.
27. Home Office. British Crime Survey. Drug Misuse Declared: Findings from the 2011/12 Crime Survey for England and Wales (2nd Edition). http://www.statistics.gov.uk,http://www.homeoffice.gov.uk/science_research.2012.
28. Degenhardt L, Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy 2008; 19: 311-316.
29. Wood DM, Greene SL, et al. Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. Epub ahead of print. Eur J Emerg Med 2012.
30. Vogels N, Croes E. Monitor Drugs Incidenten: factsheet 2011. Trimbos-instituut, Utrecht. 2012.
31. Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011; 3: 417-425.
32. Van Sassenbroeck DK, De NN, De PP, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45: 533-538.
33. Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20: 521-530.
34. Krul J, Girbes ARJ. Gamma-hydroxybutyrate: Experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin Tox 2011; 49: 311-315.
35. Galicia M, Nogue S, Miró O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011; 28: 462-466.
36. Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: Patterns of use, effects and withdrawal. Am J Addict 2001; 10: 232-241.
37. Zvosec DL, Smith S, Porrata T, et al. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2010; 29: 319-332.
38. Snead OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352: 2721-2732.
39. McDonough M, Kennedy N, Glasper A, et al. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75: 3-9.
40. Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005; 19: 195-204.
41. Weerts EM, Goodwin AK, Griffiths RR, et al. Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) 2005; 179: 678-687.
42. Watson J, Guzzetti S, Franchi C, et al. Gamma-hydroxybutyrate does not maintain self-administration but induces conditioned place preference when injected in the ventral tegmental area. Int J Neu-ropsychopharmacol 2010; 13: 143-153.
43. Goodwin AK, Kaminski BJ, Weerts EM. Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psy-chopharmacology (Berl) 2013; 225: 637-646.
44. Goodwin AK, Griffiths RR, Brown PR, et al. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacology (Berl) 2006; 189: 71-82.
45. Goodwin AK, Kaminski BJ, Griffiths RR, et al. Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend 2011; 114: 217-224.
46. Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006; 48: 219-220.
47. Veerman SRT, Dijkstra HN, Liefting-Kluft I. Levensbedreigende onthoudingsverschijnselen door gammahydroxyboterzuur. Tijdschr Psychiatrie 2010; 52: 411-416.
48. van Noorden MS, Kamal R, de Jong CAJ, et al. Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment] GHB-afhankelijkheid en -onthoudingssyndroom: diagnostiek en behandeling. Ned Tijdschr Geneeskd 2010; 154: A1286.
49. van Noorden MS, van Dongen LC, Zitman FG, et al. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiat 2009; 31: 394-396.
50. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37: 147-153.
51. Vayer P, Mandel P, Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci 1987; 41: 1547-1557.
52. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-361.
53. Snead OC, Furner R, Liu CC. In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem Pharmacol 1989; 38: 4375-4380.
54. Thai D, Dyer JE, Benowitz NL, et al. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol 2006; 26: 524-529.
55. Andresen H, Aydin BE, Mueller A, et al. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3: 560-568.
56. Palmer RB. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate. Toxicol Rev 2004; 23: 21-31.
57. Carter LP, Wu H, Chen W, et al. Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptors. J Pharmacol Exp Ther 2004; 308: 182-188.
58. Goodwin AK, Brown PR, Jansen EEW, et al. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 2009; 204: 465-476.
59. Arena C, Fung HL. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 1980; 69: 356-358.
60. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol 1992; 23: 1027-1034.
61. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuro-modulator gamma-hydroxybutyrate (GHB). FASEB J 2003; 17: 1691-1693.
62. Andriamampandry C, Taleb O, Kemmel V, et al. Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB J 2007; 21: 885-895.
63. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992; 572: 345-348.
64. Castelli MP, Ferraro L, Mocci I, et al. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular gluta-mate in the hippocampus, but fail to activate G protein and to pro-duce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem 2003; 87: 722-732.
65. Carai MA, Colombo G, Gessa GL. Protection by the GABAB receptor antagonist, SCH 50911, of gamma-hydroxybutyric acid-induced mortality in mice. Eur J Pharmacol 2004; 503: 77-80.
66. Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 2003; 18: 2722-2730.
67. Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 2009; 121: 100-114.
68. Black J, Pardi D, Hornfeldt CS, et al. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009; 10: 829-835.
69. Galloway GP, Frederick-Osborne SL, Seymour R, et al. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 2000; 20: 263-269.
70. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986; 9: 285-289.
71. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev 2011; 15: CD008537.
72. Sumnall HR, Woolfall K, Edwards S, et al. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend 2008; 92: 286-290.
73. Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010; CD006266.
74. Caputo F, Bernardi M. Medications acting on the GABA system in the treatment of alcoholic patients. Curr Pharm Des 2010; 16: 2118-2125.
75. Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 2009; 206: 141-154.
76. Carter LP, Pardi D, Gorsline J, et al. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 2009; 104: 1-10.
77. Ramo DE, Grov C, Delucchi K, et al. Typology of club drug use among young adults recruited using time-space sampling. Drug Alcohol Depend 2010; 107: 119-127.
78. de Jong CAJ, Kamal R, Dijkstra BAG, et al. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur Addict Res 2012; 18: 40-45.
79. Brunt TM, Brunt TM, Koeter MW, et al. Sociodemographic and substance use characteristics of gamma hydroxybutyrate (GHB) dependent inpatients and associations with dependence severity. Drug Alcohol Depend 2013.
80. Xi ZX, Ramamoorthy S, Shen H, et al. GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 2003; 23: 3498-3505.
81. Jayaram P, Steketee JD. Effects of repeated cocaine on medial prefrontal cortical GABAB receptor modulation of neurotransmis-sion in the mesocorticolimbic dopamine system. J Neurochem 2004; 90: 839-847.
82. Nabben T, Benschop A, Korf DJ. Antenne 2009: trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers. Available from: www.dare.uva.nl/document/223193. [Accessed 3 April 2013]. 2010.
83. Camacho A, Matthews SC, Murray CF, et al. Use of GHB compounds among college students. Am J Drug Alcohol Abuse 2005; 31: 6001-6007.
84. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. IS-POCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 1998; 351: 857-861.
85. Hibell B, Guttormsson U, Ahlström S, et al. The 2011 ESPAD Report - Substance Use Among Students in 36 European Countries. http://www.espad.org/en/Reports--Documents/ESPAD-Reports/. 2012.
86. Degenhardt L, Hall WD, Lynskey M, et al. Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med 2009; 6: e1000133.
87. Voorham L, Buitenhuis S. GHB-gebruik(ers) in beeld. Een type-ring van de GHB-gebruiker en hun bereikbaarheid. Trimbos-instituut, Utrecht, The Netherlands. 2012.
88. Korf DJ, Nabben T, Leenders F, et al. GHB: Tussen Extase en Narcose, Rozenberg Publishers, Amsterdam. 2002.
89. van der Poel A, Doekhie J, Verdurmen J, et al. Feestmeter 2008-2009: uitgaan en middelengebruik onder bezoekers van party's en clubs. Utrecht/Amsterdam: Trimbos-instituut/Bonger Instituut. Available from: www.trimbos.nl. [Accessed 3 April 2013]. 2010.
90. Dick D, Torrance C. Mixmag drugs survey. Mixmag 225, pp. 44-53, 14 January 2010. 2010.
91. Parsons JT, Grov C, Kelly BC. Club drug use and dependence among young adults recruited through time-space sampling. Public Health Rep 2009; 124: 246-254.
92. Aarts M, van Melick D, Parlar D, et al. Onderzoeksrapport: GHB-gebruik in Noord-Limburg. Venray: GGZ Noord- en Midden-Limburg. 2010.
93. de Jong M, Poelmans I, Linck H, et al. Tendens 2008: alcohol- en drugsgebruik bij jongeren en jongvolwassenen in Gelderland. Arn-hem: IrisZorg. http://www.iriszorg.nl/sites/iriszorg.nl/files/field/at-tach/tendens_2008.pdf. [Accessed 3 April 2013]. 2008.
94. Degenhardt L, Darke Sh, Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 2003; 98: 199-204.
95. Dijkstra BAG, de Weert van Oene G, Verbrugge CAG, et al. GHB Detoxificatie met farmaceutische GHB. Eindrapportage van de mi\onitoring van DeTiTap in de Nederlandse verslavingszorg. NISPA. Nijmegen. http://www.nispa.nl/sites/default/files/2013_03_18%20Presentatie%20GHB%20monitor%20 eindcon-gres%20BD.pdf. [Accessed 3 April 2013]. 2013.
96. Devlin RJ, Henry JA. Clinical review: Major consequences of illicit drug consumption. Crit Care 2008; 12: 202.
97. Dietze PM, Cvetkovski S, Barratt MJ, et al. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188: 709-711.
98. Krul J, Blankers M, Girbes ARJ. Substance-related health problems during rave parties in the Netherlands (1997-2008). PLoS ONE 2011; 6: e29620.
99. Zvosec DL, Smith SW, Litonjua R, et al. Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45: 261-265.
100. Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40: 781-787.
101. Galloway GP, Frederick SL, Staggers FE, et al. GHB: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92: 89-96.
102. Stein LAR, Lebeau R, Clair M, et al. Preliminary web-based measures development for GHB: expectancies, functions, and withdrawal. Am J Drug Alcohol Abuse 2012; 38: 121-129.
103. Johnson MW, Johnson MW, Griffiths RR, et al. Comparative Abuse Liability of GHB and Ethanol in Humans. Exp Clin Psycho-pharmacol 2013.
104. Miró O, Nogué S, Espinosa G, et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40: 129-135.
105. Colombo G, Agabio R, Lobina C, et al. Symmetrical generalization between the discriminative stimulus effects of gamma-hydroxybutyric acid and ethanol: occurrence within narrow dose ranges. Physiol Behav 1995; 57: 105-11.
106. Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012; 50: 458-470.
107. Kamal R. Afkicken van GHB: levensgevaarlijk. Ned Tijdschr Ge-neeskd 2010; 154: A1286.
108. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001; 63: 1-22.
109. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008; 10: 69-74.
110. Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106: 442-447.
111. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002; 23: 151-156.
112. Beardsley PM, Balster RL, Harris LS. Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacology (Berl) 1996; 127: 315-32.
113. Carter LP, Flores LR, Wu H, et al. The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies. J Pharmacol Exp Ther 2003; 305: 668-674.
114. Koek W, Carter LP, Lamb RJ, et al. Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. J Pharmacol Exp Ther 2005; 314: 170-179.
115. Martellotta MC, Fattore L, Cossu G, et al. Rewarding properties of gamma-hydroxybutyric acid: an evaluation through place preference paradigm. Psychopharmacology (Berl) 1997; 132: 1-5.
116. Colombo G, Gessa GL. Gamma-hydroxybutyric acid in alcohol preference, dependence and withdrawal. Addict Biol 2000; 5: 389-403.
117. Bania TC, Ashar T, Press G, et al. Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 2003; 10: 697-704.
118. Van Sassenbroeck DK, De Paepe P, Belpaire FM, et al. Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects. J Pharm Pharmacol 2003; 55: 609-615.
119. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011; 69: 650-663.
120. Gessa GL, Crabai F, Yargiu L, et al. Selective increase of brain dopamine induced by gamma-hydroxybutyrate: study of the mechanism of action. J Neurochem 1968; 15: 377-381.
121. Aghajanian GK, Roth RH. Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy. J Pharmacol Exp Ther 1970; 175: 131-8.
122. Walters JR, Roth RH. Effect of gamma-hydroxybutyrate on dopa-mine and dopamine metabolites in the rat striatum. Biochem Pharmacol 1972; 21: 2111-2121.
123. Erhardt S, Andersson B, Nissbrandt H, et al. Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by gamma-hydroxybutyric acid (GHBA) are specifically induced by activation of GABA(B) receptors. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 611-619.
124. Roth RH, Doherty JD, Walters JR. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons? Brain Res 1980; 189: 556-50.
125. Schmidt-Mutter C, Muller C, Zwiller J, et al. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsy-chopharmacology 1999; 21: 662-669.
126. Diana M, Mereu G, Mura A, et al. Low doses of gamma-hydroxybutyric acid stimulate the firing rate of dopaminergic neurons in unanesthetized rats. Brain Res 1991; 566: 208-211.
127. Fattore L, Cossu G, Martellotta MC, et al. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 2002; 37: 495-498.
128. Crunelli V, Emri Z, Leresche N. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 2006; 6: 44-52.
129. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1996; 218: 5-8.
130. Madden TE, Johnson SW. Gamma-hydroxybutyrate is a GABAB receptor agonist that increases a potassium conductance in rat ventral tegmental dopamine neurons. J Pharmacol Exp Ther 1998; 287: 261-265.
131. Cruz HG, Ivanova T, Lunn ML, et al. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004; 7: 153-159.
132. Labouebe G, Lomazzi M, Cruz HG, et al. RGS2 modulates coupling between GABAB receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat Neurosci 2007; 10: 1559-1568.
133. Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol 2012; 26: 205-212.
134. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8: 430-433.
135. Morse BL, Vijay N, Morris ME. gamma-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol 2012; 82: 226-235.
136. Szabo ST, Gold MS, Goldberger BA, et al. Effects of sustained gamma-hydroxybutyrate treatments on spontaneous and evoked firing activity of locus coeruleus norepinephrine neurons. Biol Psychiatry 2004; 55: 934-939.
137. Wisselink DJKWG, Kuijpers WGT, Mol A. Kerncijfers versla-vingszorg. National Information System on Alcohol and Drugs (LADIS), Stichting Informatie Voorziening Zorg (IVZ). http://www.sivz.nl/images/documenten/kerncijfers/kerncijfers%20verslavingszorg%202012.pdf. 2012.
138. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev 2004; 23: 45-49.
139. Sivilotti ML, Burns MJ, Aaron CK, et al. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38: 660-665.
140. Fattore L, Cossu G, Martellotta MC, et al. Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. Neuroreport 2001; 12: 2243-2246.
141. Amato L, Davoli M, Ferri M, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2004; CD003409.
142. Agboola S, McNeill A, Coleman T, et al. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105: 1362-1380.
143. Penberthy JK, Ait-Daoud N, Vaughan M, et al. Review of treatment for cocaine dependence. Curr Drug Abuse Rev 2010; 3: 49-62.
144. Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci 2013; 13: 583-609.
145. Mercer JW, Oldfield LS, Hoffman KN, et al. Comparative analysis of gamma-hydroxybutyrate and gamma-hydroxyvalerate using GC/MS and HPLC. J Forensic Sci 2007; 52: 383-388.
146. Carter LP, Chen W, Wu H, et al. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend 2005; 78: 91-99.